Aldagen, UC-Davis Pact Aims to Develop Rx Candidates for Neural, Vascular Diseases | GenomeWeb
Biotech firm Aldagen and the University of California-Davis said this week that they plan to investigate if Aldagen’s adult stem-cell population can be used in a preclinical rat model of ischemic stroke, and if it can eventually play a role in creating drugs for other kinds of vascular or neurological disorders.
 
The collaboration will be the first to involve researchers at the UC-Davis Institute for Regenerative Cures, a new $62 million facility supported by the California Institute for Regenerative Medicine.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In Science this week: genetic target for urothelial bladder cancer treatment, and more.

At the Conversation, the University of Oxford's Michael Macklay writes that learning genetic risk of disease is a personal decision.

Two dozen scientific organizations have endorsed the March for Science, according to ScienceInsider.

Researchers in Japan describe a chimpanzee with a chromosomal abnormality similar to human Down syndrome, Mashable reports.